A new rapid and sensitive LC-MS assay for the determination of sorafenib in plasma: Application to a patient undergoing hemodialysis

Therapeutic Drug Monitoring

Volumn 33, Issue 6, 2011, Pages 705-710

  Bobin Dubigeon, Christine ^a,b   Heurgue Berlot, Alexandra ^c   Bouche, Olivier ^c   Amiand, Marie Bernadette ^a   Guellec, Chantal Le ^d   Bard, Jean Marie ^a,b  

^a UMR INSERM U892 CNRS 6299   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c SERVICE DE DERMATOLOGIE   (France)

^d UNIVERSITÉ DE TOURS   (France)

Author keywords

Hemodialysis; Liquid chromatography mass spectrometry; Pharmacokinetics; Sorafenib

Indexed keywords

ACETONITRILE; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; FORMIC ACID; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; NAVELBINE; OXALIPLATIN; SORAFENIB; VINCRISTINE; VINDESINE;

ACCURACY; ADULT; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG DETERMINATION; FOOD AND DRUG ADMINISTRATION; GRAFT DYSFUNCTION; HAND FOOT SYNDROME; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; SOLID PHASE EXTRACTION;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CALIBRATION; CARCINOMA, HEPATOCELLULAR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; FATAL OUTCOME; HUMANS; KIDNEY FAILURE, CHRONIC; LIMIT OF DETECTION; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS; SOLID PHASE EXTRACTION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84856100028     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182357891     Document Type: Article

References (18)

1. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109. (Pubitemid 39331023)
2. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
3. Van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35:692-706.
4. Nowatzke W, Woolf E. Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples. AAPS J. 2007;9:E117-E22.
5. US Department of Health and Human Services. Guidance for Industry Bioanalytical Method Validation from FDA. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, CDER; 2001.
6. Jain L, Gardner ER, Venitz J, et al. Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma. J Pharm Biomed Anal. 2008;46:362-367.
7. Sparidans RW, Vlaming ML, Lagas JS, et al. Liquid chromatographytandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:269-276.
8. Zhao M, Rudek MA, He P, et al. A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;846:1-7. (Pubitemid 46149480)
9. Li L, Zhao M, Navid F, et al. Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatographytandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:3033-3038.
10. Blanchet B, Billemont B, Cramard J, et al. Validation of an HPLC-UV method for sorafenib determination inn human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal. 2009;49:1109-1114.
11. Heinz WJ, Kahle K, Helle-Beyersdorf A, et al. High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. Cancer Chemother Pharmacol. 2010;68:239-245.
12. Haouala A, Zanolari B, Rochat B, et al. Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:1982-1996.
13. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23:965-972. (Pubitemid 46202316)
14. Rey PM, Villavicencio H. Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience. Oncology. 2008;74:245-246.
15. Shinsako K, Mizuno T, Terada T, et al. Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study. Int J Clin Oncol. 2010;15:512-514.
16. Hilger RA, Richly H, Grubert M, et al. Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis. Int J Clin Pharmacol Ther. 2009;47:61-64.
17. Burton ME, Shaw LM, Shentag JJ, et al. Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2006.
18. Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009;27:1800-1805.